Drug Search Results
More Filters [+]

Cobimetinib

Alternative Names: cobimetinib, gdc-0973, cotellic
Latest Update: 2024-10-12
Latest Update Note: Clinical Trial Update

Product Description

Cobimetinib is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cobimetinib)

Mechanisms of Action: MAP2K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Noma | Melanoma

Known Adverse Events: Lymphopenia | Hyponatremia | Hypophosphatemia | Diarrhea

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cobimetinib

Countries in Clinic: Algeria, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Kazakhstan, Kenya, Korea, Latvia, Mexico, Netherlands, New Zealand, Norway, Panama, Peru, Poland, Portugal, Romania, Russia, Serbia, Singapore, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States

Active Clinical Trial Count: 43

Highest Development Phases

Phase 3: Anaplastic Thyroid Carcinoma|Colorectal Cancer|Erdheim-Chester Disease|Glioma|Laryngeal Cancer|Lymphoproliferative Disorders|Melanoma|Multiple Myeloma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Ovarian Diseases|Papillary Carcinoma|Rectal Diseases|Thyroid Cancer

Phase 2: Abnormalities, Multiple|Adenocarcinoma|Arteriovenous Malformations|Bladder Cancer|Brain Cancer|Breast Cancer|Bronchial Cancer|Bronchogenic Carcinoma|Cervical Cancer|Chronic Myelomonocytic Leukemia|Esophageal Cancer|Esophageal Diseases|Gastrointestinal Cancer|Hairy Cell Leukemia|Hemangioma|Histiocytic Disorders, Malignant|Histiocytic Sarcoma|Histiocytosis, Langerhans-Cell|Histiocytosis, Sinus|Hodgkin Lymphoma|Intestinal Cancer|Intestinal Diseases|Juvenile Myelomonocytic Leukemia,|Langerhans Cell Sarcoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified|Oncology Unspecified|Pancreatic Cancer|Respiratory Tract Cancer|Sarcoma|Skin Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Thoracic Cancer|Tic Disorders|Vision, Low|Xanthogranuloma, Juvenile

Phase 1: Pancreatic Ductal Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DETERMINE

P3

Recruiting

Lymphoproliferative Disorders

2029-10-01

DETERMINE

P3

Recruiting

Ovarian Diseases|Papillary Carcinoma|Laryngeal Cancer|Non-Small-Cell Lung Cancer|Rectal Diseases|Glioma|Multiple Myeloma|Ovarian Cancer|Thyroid Cancer|Colorectal Cancer|Erdheim-Chester Disease|Anaplastic Thyroid Carcinoma|Melanoma

2029-10-01

BO29554

P3

Unknown Status

Non-Small-Cell Lung Cancer

2028-08-03

B-FAST

P3

Recruiting

Non-Small-Cell Lung Cancer

2028-08-03

Recent News Events